Rong Zhai

TL;DR: H6 is a novel and potent MDR reversal agent, which has the potential to be administered in combination with conventional anticancer drugs and demonstrates robust reversal activity against MDR in vitro and in vivo.

TL;DR: This study highlights the advantage of introducing the medium-length amino-terminal groups at the 3-OH position of FA to enhance its anti-tumor activity and suggests that compound 4 provides a starting point for designing more potent derivatives in the future.

TL;DR: The present studies highlight the importance of polyamine derivatives of α-hederagenin in the discovery and development of novel anticancer agents.

TL;DR: A series of novel H6 analogues were designed and synthesized with the aim of improving the drug resistant reversal activity of H6 and compound 10 enhanced the efficacy of paclitaxel against KBV cancer cell-derived xenograft tumors and found that compound 10 might block the drug efflux of P-gp via stimulating P- gp ATPase activity.